WallStSmart

Abbott Laboratories (ABT)vsGeneral Dynamics Corporation (GD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

General Dynamics Corporation generates 19% more annual revenue ($53.81B vs $45.13B). ABT leads profitability with a 13.9% profit margin vs 8.1%. ABT appears more attractively valued with a PEG of 1.29. GD earns a higher WallStSmart Score of 60/100 (C+).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

GD

Buy

60

out of 100

Grade: C+

Growth: 6.7Profit: 6.5Value: 3.3Quality: 7.0
Piotroski: 6/9Altman Z: 2.95
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
GDSignificantly Overvalued (-22.2%)

Margin of Safety

-22.2%

Fair Value

$293.63

Current Price

$346.53

$52.90 premium

UndervaluedFair: $293.63Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

GD2 strengths · Avg: 8.5/10
Market CapQuality
$93.71B9/10

Large-cap with strong market position

Free Cash FlowQuality
$1.95B8/10

Generating 2.0B in free cash flow

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

GD1 concerns · Avg: 2.0/10
PEG RatioValuation
2.582/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : GD

The strongest argument for GD centers on Market Cap, Free Cash Flow. Revenue growth of 10.3% demonstrates continued momentum.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : GD

The primary concerns for GD are PEG Ratio.

Key Dynamics to Monitor

ABT carries more volatility with a beta of 0.65 — expect wider price swings.

GD is growing revenue faster at 10.3% — sustainability is the question.

GD generates stronger free cash flow (2.0B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GD scores higher overall (60/100 vs 56/100) and 10.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

General Dynamics Corporation

INDUSTRIALS · AEROSPACE & DEFENSE · USA

General Dynamics Corporation (GD) is an American aerospace and defense corporation. It is headquartered in Reston, Fairfax County, Virginia.

Visit Website →

Want to dig deeper into these stocks?